[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-to-moderate-asthma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-to-moderate-asthma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100618373","phase-1-a-study-of-cdx-622-in-participants-with-mild-to-moderate-asthma-100618373",false,"NCT07330778","A Study of CDX-622 in Participants With Mild to Moderate Asthma","An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma","Key Inclusion Criteria:\n\n1. Males and females, ≥ 18 years of age\n2. Diagnosis of mild to moderate asthma for at least 12 months\n3. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal\n4. Airway reversibility ≥ 12% and 200 mL improvement in FEV1\n5. Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment\n6. Willing and able to comply with all study requirements and procedures\n\nKey Exclusion Criteria:\n\n1. Females who are pregnant or nursing\n2. Pulmonary disease other than asthma\n3. Systemic diseases with elevated eosinophils other than asthma\n4. Hospitalization for treatment of asthma in the past 12 months or required oral corticosteroids due to asthma within the past 6 months\n5. History of needing ventilator support due to asthma\n6. Current nasal polyps\n7. Severe or uncontrolled asthma\n8. History of smoking or vaping within the past 6 months\n9. Tuberculosis, hepatitis B or C virus, or HIV\n10. Immunomodulating biologic therapies within the past 3 months for non-extended half-life biologics.\n11. Prior receipt of TSLP or KIT inhibitors such as tezepelumab or briquilimab\n\nAdditional protocol defined inclusion and exclusion criteria could apply.","ALL","18 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.",[26],"Mild to Moderate Asthma",[28,29,30],"Asthma","Mild to moderate","CDX-622","RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-06-01",{"date":39,"type":20},"2027-03",{"name":41,"class":42},"Celldex Therapeutics","INDUSTRY",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100619999","remission-in-adults-with-mild-to-moderate-asthma-in-thailand-100619999","NCT07351916","Remission in Adults With Mild-to-moderate Asthma in Thailand","Inclusion Criteria:\n\n* mild-to-moderate asthma\n* age 18 years or older\n\nExclusion Criteria:\n\n* inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test",{"count":51,"type":20},289,"OBSERVATIONAL","The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand.\n\nThe main question the study aims to answer is:\n\nWhat is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.",[28,55,56],"Mild-to-moderate Asthma","Asthma Control Level",[58,59,60,61,62,63,64],"asthma","asthma control","mild-to-moderate asthma","Thailand","remission","FeNO","blood eosinophil count","2026-04-15",{"date":67,"type":35},"2026-04-17",{"date":69,"type":35},"2026-02-01",{"date":71,"type":20},"2026-12-31",{"name":73,"class":74},"Thammasat University","OTHER",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100611806","phase-1-study-of-pra-216-in-healthy-participants-and-participants-with-mild-to-moderate-asthma-100611806","NCT07245368","Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma","A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending and Multiple Ascending Dose Study Investigating PRA-216 in Healthy Volunteers Followed by a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study in Participants With Mild-to-Moderate Asthma","Phase 1\n\nInclusion Criteria:\n\n* Age 18-65\n* Must be in good health with no significant medical history\n* Willing and able to attend all study visits, comply with study requirements\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Evidence of clinically significant condition or disease\n* Any physical or psychological condition that prohibits study completion\n* Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism, and\u002For smoking or nicotine-containing product use within 3 months prior to the first dose of study agent\n* History of severe allergic reactions or hypersensitivity\n* Donation or loss of ≥ 1 unit of whole blood or plasma within 2 months prior to dosing\n\nPhase 2a\n\nInclusion criteria:\n\n* Age 18-65\n* Must be in good health with no significant medical history\n* Willing and able to attend all study visits, comply with study requirements.\n* Able and willing to provide written informed consent\n* Documented asthma diagnosis prior for at least 12 months prior to screening.\n* Symptomatic asthma\n* Currently receiving maintenance asthma medications\n\nExclusion Criteria:\n\n* Evidence of clinically significant condition or disease\n* Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism, and\u002For smoking or nicotine-containing product use within 3 months prior to the first dose of study agent\n* Donation or loss of ≥ 1 unit of whole blood or plasma within 2 months prior to dosing\n* History of severe allergic reactions or hypersensitivity\n* Current or former smoker with a smoking history of ≥10 pack-years\n* Receipt of immunosuppressant therapies or biologic therapy for asthma within 6 months of screening\n* Other investigational agent(s) within 30 days of dosing",true,"65 Years",{"count":86,"type":20},96,[23,88],"PHASE2","Phase 1 of this study will consist of 2 parts\n\n* Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC).\n* Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously.\n\nPhase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.",[26],[92,93,94,58,95],"healthy volunteers","pharmacodynamics","immunogenicity","pharmacokinetics","2026-03-18",{"date":98,"type":35},"2026-03-20",{"date":100,"type":35},"2025-11-04",{"date":102,"type":20},"2027-01-31",{"name":104,"class":42},"Prana Therapies Inc",7]